Trifluoroibuprofen Inhibits &amp;#945;-Methylacyl Coenzyme A Racemase (AMACR/P504S), Reduces Cancer Cell Proliferation and Inhibits in vivo Tumor Growth in Aggressive Prostate Cancer Models

Festuccia, Claudio; Gravina, Giovanni Luca; Mancini, Andrea; Muzi, Paola; Cesare, E. Di; Kirk, Ralph; Smith, Meredith; Hughes, Shaun M. G.; Gibson, Ray; Lian, Lu‐Yun; Ricevuto, Enrico; Carnell, Andrew J.

doi:10.2174/1871520614666140327152607

Cited by 20 publications

(26 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This demonstrates that AMACR can be useful in discriminating control subjects from those with PCa (Sreekumar et al, 2004). Interestingly, it has been described, that trifluoroibuprofen, an AMACR inhibitor, reduces cancer cell proliferation and Inhibits in vivo tumor growth in aggressive PCa models (Festuccia et al, 2014). This makes AMACR one of possible therapeutical targets in future.…”

Section: α-Methylacyl Coenzyme a Racemase (Amacr)mentioning

confidence: 79%

Novel Biomarkers in Determining Prostate Cancer Diagnosis and Prognosis

Nováková¹,

Bevizova²,

Gašparová³

2014

OnLine Journal of Biological Sciences

View full text Add to dashboard Cite

Abstract:The clinical behavior and molecular pathology of prostate cancer is highly variable. Current "traditional" prognostic markers cannot reliably distinguish the potentially life-threatening cancer from indolent cancer. Identification of additional new predictors of cancer aggressiveness is therefore urgently required. This communication is aimed at a brief review of new biomarkers in prostate cancer diagnostics and prognostics. Pubmed systematic search was performed to collect both original and review articles addressing prostate cancer prognostic biomarkers using key words genetics, prostate cancer, biomarkers and prognosis. The development of molecular and immunohistochemical methods enabled the identification of potential biomarkers in relation to diagnosis and prognosis. Numerous promising markers and approaches have been identified. Some of these markers may be translated into clinical practice after verification in larger prospective trials in future and can help to determine diagnosis and prognosis of CaP more accurately.

show abstract

Section: α-Methylacyl Coenzyme a Racemase (Amacr)mentioning

confidence: 79%

Novel Biomarkers in Determining Prostate Cancer Diagnosis and Prognosis

Nováková¹,

Bevizova²,

Gašparová³

2014

OnLine Journal of Biological Sciences

View full text Add to dashboard Cite

show abstract

“…The overexpression of AMACR was shown to be associated with the aggressive behavior of multiple human cancers [16][17][18][19][20][21][22][23][24][25]. In vitro, AMACR was shown to increase cell growth and proliferation [26]. CCNH-C5orf30 and TRMT11-GRIK2 belong to a class of fusion genes with loss of function.…”

Section: Discussionmentioning

confidence: 99%

Detection of fusion transcripts in the serum samples of patients with hepatocellular carcinoma

Tsung

Liu

et al. 2019

Oncotarget

View full text Add to dashboard Cite

Hepatocellular carcinoma is one of the most lethal cancers in the United States. Early detection of the disease is crucial for reducing the mortality of this malignancy. Recently, we identified a panel of fusion genes present in several types of human cancers, including hepatocellular carcinoma. Among 8 fusion genes, MAN2A1-FER, TRMT11-GRIK2 and CCNH-C5orf30 appear most frequently in hepatocellular carcinoma samples. In this study, we showed that the fusion transcripts of MAN2A1-FER, CCNH-C5orf30 and SLC45A2-AMACR were detected in the serum samples of liver cancer patients as circulating cell-free RNA. The distributions of these gene fusion RNA fragments largely matched those of the primary HCC samples. In contrast, the sera of all healthy individuals free of human malignancies were shown to be negative for these fusion genes. These results suggest that gene fusion RNA is frequently shed from liver cancer cells. The detection of serum cell-free fusion transcripts may provide a new approach to aid in the diagnosis, follow-up or therapy of liver cancers.

show abstract

“…of FAs has been linked to tumor promotion in pancreatic cancer ( 53 ). Pharmacological inhibition of ␣ -methylacylCoA racemase (AMACR), implicated in the oxidation of branched chain FAs, induces cell growth arrest and apoptosis in PCa ( 54,55 ) and androgen upregulation of carnitine palmitoyltransferase (CPT)1 in PCa leads to increased mitochondrial FAO and ROS production that it has been associated with cell proliferation ( 56 ). Highly metastatic breast cancer cells rely partially on FAO induced by AMPK activation ( 54,57 ).…”

Section: Lipogenesis and Cholesterogenesismentioning

confidence: 99%

Microtargeting cancer metabolism: opening new therapeutic windows based on lipid metabolism

Cedrón

Molina

2016

Journal of Lipid Research

View full text Add to dashboard Cite

and fl exibility to adapt to the microenvironment (oxygen, pH, and nutrient availability) ( 2-4 ).MicroRNAs are small single-stranded noncoding RNAs (19-25 nucleotides) that posttranscriptionally repress the expression of mRNAs implicated in nearly all cellular processes, such as cell cycle, apoptosis, autophagy, stemness, differentiation, angiogenesis, infl ammation, drug resistance, stress response, transformation, and migration. MicroRNAs are frequently deregulated in cancer and so they are important biomarkers for diagnosis and prognosis of the cellular outcome ( 5,6 ) Importantly, individual microRNAs, combinations of microRNAs, or even artifi cial microRNAs can specifi cally be designed to affect entire biological pathways ( 7,8 ), and this makes them good candidates for therapeutic intervention compared with classical single target approaches.In this review, we briefl y describe the altered cancer cell metabolism, and then we discuss the use of microRNAs as modulators of specifi c metabolic pathways in cancer (summarized in Fig. 1 ). We note the promising potentiallity of microRNAs for therapeutic intervention toward the altered lipid metabolism in cancer (summarized in Fig. 2 ). In an attempt to open new therapeutic windows, we emphasize two exciting scenarios for microRNA-mediated intervention that need to be further explored: 1 ) the cooperation between FA biosynthesis (lipogenesis) and FA oxidation (FAO) as a survival mechanism in cancer; and 2 ) the regulation of the intracellular lipid content in the Abstract Metabolic reprogramming has emerged as a hallmark of cancer. MicroRNAs are noncoding RNAs that posttranscriptionally repress the expression of target mRNAs implicated in multiple physiological processes, including apoptosis, differentiation, and cancer. MicroRNAs can affect entire biological pathways, making them good candidates for therapeutic intervention compared with classical single target approaches. Moreover, microRNAs may become more relevant in the fi ne-tuning adaptation to stress situations, such as oncogenic events, hypoxia, nutrient deprivation, and oxidative stress. Furthermore, artifi cial microRNAs can be designed to modulate the expression of multiple targets of a specifi c pathway. In this review, we describe the metabolic reprogramming associated to cancer, with a special interest in the altered lipid metabolism. Next, we describe specifi c features of microRNAs that make them relevant to target cancer cell metabolism. Finally, in an attempt to open new therapeutic windows, we emphasize two exciting scenarios for microRNA-mediated intervention that need to be further explored: 1 ) the cooperation between FA biosynthesis (lipogenesis) and FA oxidation as complementary partners for the survival of cancer cells; and 2 ) the regulation of the intracellular lipid content modulating both lipid storage into lipid droplets, and lipid mobilization through lipolysis and/or lipophagy. metabolism is interrupted, they may rely on glucose-dependent anaplerosis of the TCA cycle ( 11 ). This...

show abstract

Trifluoroibuprofen Inhibits α-Methylacyl Coenzyme A Racemase (AMACR/P504S), Reduces Cancer Cell Proliferation and Inhibits in vivo Tumor Growth in Aggressive Prostate Cancer Models

Abstract: AMACR is a good pharmacological target for treatment of PCa and TFIP is a suitable anticancer compound with parenteral administration being the preferred route.

Cited by 20 publications

References 0 publications

Novel Biomarkers in Determining Prostate Cancer Diagnosis and Prognosis

Novel Biomarkers in Determining Prostate Cancer Diagnosis and Prognosis

Detection of fusion transcripts in the serum samples of patients with hepatocellular carcinoma

Microtargeting cancer metabolism: opening new therapeutic windows based on lipid metabolism

Contact Info

Product

Resources

About